Download Antonio La Cava 1912 Broadway, Apt. 301 Santa Monica

CURRICULUM VITAE
FORMATO EUROPEO/EUROPEAN FORMAT
INFORMAZIONI PERSONALI/
PERSONAL INFORMATION
Nome, Cognome/Name, Surname
Indirizzo/Address
Via, numero civico, c.a.p., città,
nazione/ House number, street
name, postcode, city, country
Telefono/Telephone
Fax
E-mail
Antonio La Cava
1912 Broadway, Apt. 301
Santa Monica, California 90404
USA
+1 310 267-4975
+1 310 206-8606
[email protected]
Sito web/Website
Nazionalità/Nationality
Luogo e data di nascita/ Place and
Date of birth
Italian
Monza (MI), Italy
December 10, 1960
ESPERIENZA PROFESSIONALE/
WORK EXPERIENCE
Se dipendente CNR indicare:
In ordine di data /Dates (from – to)
[Iniziare con le più recenti ed
elencare separatamente ciascun
incarico ricoperto/ Add separate
entries for each relevant post
occupied, starting with the most
recent. ]
Nome e indirizzo del datore di lavoro
/ Name and address of employer
Tipo o settore di attività / Type of
business or sector
Funzione o posto occupato /
Occupation or position held
Page 1 - Curriculum vitae
di [cognome] / of [surname]
N. MATRICOLA
QUALIFICA
LIVELLO
• 2009-present: Director of the University of California Los Angeles (UCLA) Center of
Excellence for the Federation of Clinical Immunology Societies
• 2010-present: Professor, Division of Rheumatology, Department of Medicine, UCLA
• 2005-2009: Associate Professor, Division of Rheumatology, Department of Medicine, UCLA
• 2005-present: Director of the Lupus Research Laboratory at UCLA
• 2001-2005: Assistant Professor, Division of Rheumatology, Department of Medicine, UCLA
• 1998–2001: Research Associate, Department of Immunology, The Scripps Research Institute,
La Jolla, California
• 1993-1997: Postgraduate Research Immunologist, Department of Medicine, University of
California San Diego
• 1989-1993: Postdoctoral Fellow, Department of Cellular and Molecular Biology and Pathology,
School of Medicine, "Federico II" University of Naples, Italy
University of California Los Angeles
1000 Veteran Ave. 32-59, Los Angeles, California 90095-1670, USA
University, School of Medicine
Professor
Principali mansion e responsabilità /
Main activities and responsibilities
Research, Teaching, Administration
ISTRUZIONE E FORMAZIONE /
EDUCATION AND TRAINING
In ordine di data /Dates (from – to)
[Iniziare con le più recenti ed
elencare separatamente ciascun
corso frequentato con successo/ Add
separate entries for each relevant
course you have completed, starting
with the most recent. ]
Nome e tipo d’istituto di istruzione o
formazione / Name and type of
organisation providing education and
training
Principali materie e competenze
professionali apprese / Principal
subjects occupational skills covered
Certificato o diploma ottenuto /Title of
qualification awarded
Livello nella classificazione nazionale
o internazionale / Level in National
classification
• October 17, 1995: Doctorate (Ph.D.) in Cellular and Molecular Biology and Pathology
• April 14, 1989: M. D. summa cum laude
• September 1989: License for medical practice in Italy
University of Naples, Italy: Doctorate (Ph.D.)
School of Medicine, "Federico II" University of Naples, Italy: M.D.
Medicine, Biomedical Research
M.D., Ph.D.
N/A
ATTIVITA’ DI RICERCA /
RESEARCH ACTIVITIES
Attuali campi di ricerca / Research
sectors
Autoimmune diseases
Recenti attività scientifiche/ Recent
Scientific Activities.
Scientific research
ULTERIORI INFORMAZIONI /
ADDITIONAL INFORMATION
Page 2 - Curriculum vitae
di [cognome] / of [surname]
Pubblicazioni/ Books and
Articles
Page 3 - Curriculum vitae
di [cognome] / of [surname]
Elenco delle pubblicazioni realizzate negli ultimi 5 anni:
Peer-reviewed publications:
1. Piao W-H, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI,
Vollmer TL, Bai X-F, La Cava A, Shi F-D. 2008. IL-21 modulates CD4+CD25+ regulatory Tcell homeostasis in experimental autoimmune encephalomyelitis. Scand. J. Immunol.
67:37-46.
2. Singh RP, La Cava A, Hahn BH. 2008. pConsensus peptide induces tolerogenic CD8+ T cells in
lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J.
Immunol. 180:2069-2080.
3. Liu R, Bai Y, Vollmer TL, Bai X-F, Jee Y, Tang Y-Y, Campagnolo DI, Collins M, Young DA, La
Cava A, Shi F-D. 2008. IL-21 receptor expression determines the temporal phases of
experimental autoimmune encephalomyelitis. Exp. Neurol. 211:14-24.
4. Bai Y, Liu R, Huang D, La Cava A, Tiang YY, Iwakura Y, Campagnolo DI, Vollmer TL,
Ransohoff RM, Shi F-D. 2008. CCL2 recruitment of IL-6-producing CD11b+ monocytes to
the draining lymph nodes during the initiation of Th17-dependent B cell-mediated
autoimmunity. Eur. J. Immunol. 38:1877-1888.
5. Hahn BH, Anderson M, Le E, La Cava A. 2008. Anti-DNA Ig peptides promote Treg cell
activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2488-2497.
6. Fenoglio D, Ferrera F, Fravega M, Balestra P, Battaglia F, Proietti M, Andrei C, Olive D, La
Cava A, Indiveri F, Filaci G. 2008. Advancements on phenotypic and functional
characterization of non-antigen specific CD8+CD28- regulatory T cells. Hum. Immunol.
69:745-750.
7. Wong M, Grossman J, Hahn BH, La Cava A. 2008. Cutaneous vasculitis in breast cancer
treated with chemotherapy. Clin. Immunol. 129:3-9 (featured on front cover).
8. Agrawal A, Lourenço EV, Gupta S, La Cava A. 2008. Gender-based differences in
leptinemia in healthy aging, non-obese individuals associate with increased marker of
oxidative stress. Int. J. Clin. Exp. Med. 1:305-309.
9. Lourenço EV, Procaccini C, Ferrera F, Iikuni N, Singh RP, Filaci G, Matarese G, Shi F-D,
Brahn E, Hahn BH, La Cava A. 2009. Modulation of p38 MAPK activity in regulatory T cells
after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice. J. Immunol.
182:7415-7421.
10. Iikuni N, Lourenço EV, Hahn BH, La Cava A. 2009. Cutting edge: regulatory T cells
directly suppress B cell in systemic lupus erythematosus. J. Immunol. 183:1518-1522.
11. Singh RP, Dinesh R, Elashoff D, de Vos S, Rooney RJ, Patel D, La Cava A, Hahn BH.
2010. Distinct gene signature revealed in white blood cells, CD4+ and CD8+ T cells in (NZB
x NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide. Genes Immun. 11:294309.
12. Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, Li H, Castellani LW,
Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP. 2010.
Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a
murine lupus model of accelerated atherosclerosis. Arthritis Res. Ther. 12:R93.
13. Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi F-D. 2010. Expansion of
regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia.
Eur. J. Immunol. 40:1577-1589.
14. Hahn BH, Lourenço EV, McMahon M, Skaggs B, Le E, Anderson M, Iikuni N, Lai C, La
Cava A. 2010. Pro-Inflammatory high density lipoproteins and atherosclerosis are induced
in lupus-prone mice by a high fat diet and leptin. Lupus 19:913-917.
15. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van
Kaer L, Shi F-D. 2010. Central nervous system (CNS)-resident natural killer cells suppress
Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207:1907-1921.
16. Wong M, La Cava A, Singh RP, Hahn BH. 2010. Blockade of programmed death-1 in
young (New Zealand Black x New Zealand White)F1 mice promotes the activity of
suppressive CD8+ T cells that protect from lupus-like disease. J. Immunol. 185:6563-6571.
17. Galgani M, Procaccini C, De Rosa V, Carbone F, Chieffi P, La Cava A, Matarese G. 2010.
Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energysensing mammalian target of rapamycin signalling pathway. J. Immunol. 185:7474-7479.
18. Procaccini C, De Rosa V, Galgani M, Abanni L, Calì G, Porcellini A, Carbone F, Fontana
S, Horvath TL, La Cava A, Matarese G. 2010. An oscillatory switch in mTOR kinase activity
sets regulatory T cell responsiveness. Immunity 33:929-941.
19. Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenço E, Eskin A, Liu PT,
Magpantay L, Tse S, Mahanian M, Weitzman R, Tong J, Nguyen C, Cho T, Koo P, Sayre J,
Martinez-Maza O, Rosenthal MJ, Wiedau-Pazos M. 2010. IL-17A is increased in the serum
and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflamm. 7:76.
20. Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer
L, La Cava A, Shi F-D. 2011. Interleukin-2/interleukin-2 antibody therapy induces target
organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol.
69:721-734.
21. Dinesh R, Hahn BH, La Cava A, Singh RP. 2011. Interferon-inducible gene 202b controls
CD8+ T cell-mediated suppression in anti-DNA Ig peptide treated (NZB x NZW)F1 lupus
mice. Genes Immun. 12:360-369.
22. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, CharlesSchoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La
Cava A, Hahn BH. 2011. High plasma leptin levels confer increased risk of atherosclerosis
in women with systemic lupus erythematosus, and are associated with inflammatory
oxidised lipids. Ann. Rheum. Dis. 70:1619-1624.
23. Liu SD, Lee S, La Cava A, Motran CC, Hahn BH, Miceli C. 2011. Galectin-1-induced
downregulation of T-lymphocyte activation protects (NZB x NZW)F1 mice from lupus-like
disease. Lupus 20:473-84.
24. Yu Y, Liu Y, Shi F-D, Zou H, Hahn BH, La Cava A. 2012. Tolerance induced by anti-DNA
Ig peptide in (NZB x NZW)F1 lupus mice impinges on the resistance of effector T cells to
suppression by regulatory T cells. Clin. Immunol. 142:291-5.
25. Liu Y, Yu Y, Matarese G, La Cava A. 2012. Cutting edge: Fasting-induced hypoleptinemia
expands functional regulatory T cells in systemic lupus erythematosus. J. Immunol.
188:2070-3.
26. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhay
M, La Cava A, Wiedau-Pazos M. 2012. Neuronal phagocytosis by inflammatory
macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J.
Neurodegener. Dis. 1:60-74.
27. Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, Siani A, Chan D, MartinezMaza O, Chattopadhyay M, La Cava A. 2012.Tocilizumab attenuates inflammation in ALS
patients through inhibition of IL-6 receptor signaling. Am. J. Neurodegener. Dis. 1:305-315.
28. Procaccini C, De Rosa V, Galgani M, Carbone F, Cassano S, Greco D, Qian K, Auvinen
P, Calì G, Stallone G, Formisano L, La Cava A, Matarese G. 2012. Leptin-induced mTOR
activation defines a specific molecular and transcriptional signature controlling CD4+ effector
T cell responses. J. Immunol. 189:2941-2953.
29. Wu W, Shi S, Ljunggren HG, La Cava A, Van Kaer L, Shi FD, Liu R. 2012. NK cells inhibit
T-bet-deficient, autoreactive Th17 cells. Scand. J. Immunol. 76:559-566.
30. Wu Q, Yang Q, Sun H, Li M, Zhang Y, La Cava A. 2013. Serum IFN- 1 is abnormally
elevated in rheumatoid arthritis patients. Autoimmunity 46:40-43.
31. Galgani M, Nugnes R, Bruzzese D, Perna F, De Rosa V, Procaccini C, Mozzillo E, Cilio
CM, Lernmark A, Larsson HE, La Cava A, Franzese A, Matarese G. 2013. Metaimmunological profiling of children with type 1 diabetes identifies new biomarkers to monitor
disease progression. Diabetes In press
32. Yu Y, Liu Y, Shi F-D, Zou H, Matarese G, La Cava A. Cutting edge: Leptin promotes IL-17
responses. J. Immunol. In press
33. Wong M, La Cava A, Hahn BH. Blockade of programmed death-1 (PD-1) in young (New
Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+
regulatory T cells that protect from lupus-like disease. J. Immunol. In press
Review articles:
1. Matarese G, De Rosa V, La Cava A. 2008. Regulatory CD4 T cells: sensing the
environment. Trends Immunol. 29:12-17.
2. Ferrera F, Filaci G, Rizzi M, Singh RP, Indiveri F, Hahn BH, La Cava A. 2008. New
therapies in SLE. Recent Pat. Inflamm. Allergy Drug Discov. 2:11-23.
3. Gianfrani C, Troncone R, La Cava A. 2008. Autoimmunity and celiac disease. Mini Rev.
Med. Chem. 8: 129-134.
4. La Cava A. 2008. Natural Tregs in systemic lupus erythematosus. Curr. Immunol. Rev.
4:11-19.
5. La Cava A. 2008. T-regulatory cells in systemic lupus erythematosus. Lupus 17:421-425.
6. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. 2008. Leptin and inflammation. Curr.
Immunol. Rev. 4:70-79.
7. Singh RP, Hahn BH, La Cava A. 2008. Tuning immune suppression in systemic
autoimmunity with self-derived peptides. Inflamm. Allergy Drug Targets 7:253-259.
8. La Cava A. 2008. Tregs are regulated by cytokines: Implications for autoimmunity.
Autoimmun. Rev. 8:83-87.
9. Procaccini C, Lourenço EV, Matarese G, La Cava A. 2009. Leptin signaling: A key
pathway in immune responses. Curr. Signal Transduct. Ther. 4:22-30.
10. Iikuni N, Hahn BH, La Cava A. 2009. Potential for anti-DNA immunoglobulin peptide
therapy in systemic lupus erythematosus. Expert Opin. Biol. Ther. 9:201-206.
Page 4 - Curriculum vitae
di [cognome] / of [surname]
11. La Cava A. 2009. Natural Tregs and autoimmunity. Front. Biosci. 14:333-343.
12. La Cava A. 2009. Immunotherapy with peptides in systemic lupus erythematosus. Curr.
Med. Chem. 16:1482-1488.
13. Lourenço EV, La Cava A. 2009. Cytokines in systemic lupus erythematosus. Curr. Mol.
Med. 9:242-254.
14. La Cava A. 2009. Lupus and T cells. Lupus 18:196-201.
15. Cai C, La Cava A. 2009. Mimicking self antigens with synthetic peptides in systemic
autoimmune rheumatic diseases. Curr. Clin. Pharmacol. 4:142-147.
16. Cai C, Shi F-D, Matarese G, La Cava A. 2009. Leptin as clinical target. Recent Pat.
Inflamm. Allergy Drug Discov. 3:160-166.
17. Iikuni N, La Cava A. 2009. Antibody-based therapies in systemic lupus erythematosus.
Mini Rev. Med. Chem. 9:829-846.
18. Cai C, Hahn BH, Matarese G, La Cava A. 2009. Leptin in non-autoimmune inflammation.
Inflamm. Allergy Drug Targets 8:285-291.
19. La Cava A. 2009. The busy life of regulatory T cells in systemic lupus erythematosus.
Discov. Med. 8:13-17.
20. Galgani M, Di Giacomo A, Matarese G, La Cava A. 2009. The yin and yang of CD4+
regulatory T cells in autoimmunity and cancer. Curr. Med. Chem. 16:4626-4631.
21. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. 2010. CD8+ Tregs in lupus,
autoimmunity, and beyond. Autoimmun. Rev. 9:560-568.
22. Matarese G, Procaccini C, De Rosa V, Horvat TL, La Cava A. 2010. Regulatory T cells in
obesity: the leptin connection. Trends Mol. Med. 16:247-256.
23. La Cava A. 2010. Targeting B cells with biologics in systemic lupus erythematosus.
Expert Opin. Biol. Ther. 10:1555-61.
24. Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A. 2010. Leptin as a metabolic
link to multiple sclerosis. Nat. Rev. Neurol. 6:455-461.
25. La Cava A. 2010. Modulation of autoimmunity with artificial peptides. Autoimmun. Rev.
10:18-21.
26. La Cava A. 2010. Laboratory medicine in pediatric lupus. J. Pediatr. Biochem. 1:45-51.
27. La Cava A. 2010. Anticytokine therapies in systemic lupus erythematosus.
Immunotherapy 2:575-582.
28. La Cava A, Fiala M. 2010. Curcumin and immunity. Curr. Bioact. Comp. 6:156-160.
29. La Cava A. 2011. Regulatory immune cell subsets in autoimmunity. Autoimmunity 44:12.
30. Lourenço EV, La Cava A. 2011. Natural regulatory T cells in autoimmunity.
Autoimmunity 44:33-42.
31. Wong M, La Cava A. 2011. Lupus, the current therapeutic approaches. Drug Today
47:289-302.
32. Shi F-D, Ljunggren HG, La Cava A, Van Kaer L. 2011. Organ-specific features of natural
killer cells. Nat. Rev. Immunol. 11:658-671.
33. Amarilyo G, Hahn BH, La Cava A. 2012. Preclinical studies with synthetic peptides in
systemic lupus erythematosus. Front. Biosci. 17:1940-1947.
34. Liu Y, La Cava A. 2012. Targeting BLyS in systemic lupus erythematosus. Recent Pat.
Inflamm. Allergy Drug Discov. 6:91-96.
35. Amarilyo G, La Cava A. 2012. miRNA in systemic lupus erythematosus. Clin. Immunol.
144:26-31.
36. La Cava A. 2012. The effects of curcumin on immune responses. Curr. Bioact. Comp.
8:142-145.
37. La Cava A. 2012. Proinflammatory activities of leptin in non-autoimmune conditions.
Inflamm. Allergy Drug Targets 11:298-302.
38. Matarese G, La Cava A, Horvath TL. 2012. In vivo veritas, in vitro artificia. Trends Mol.
Med. 18:439-442.
39. La Cava A. Adiponectin: a relevant player in obesity-related colorectal cancer? Gut In
press
40. Yu Y, La Cava A. Current drugs in systemic lupus erythematosus. Drug Develop. Res. In
press
41. Wu Q, La Cava A. IL-17 in systemic lupus erythematosus. Clin. Invest. In press
42. La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin. Immunol. In press
Book chapters:
1. La Cava A. 2008. Antibodies to DNA in systemic lupus erythematosus: A review and
update. In Petrelli CT (Ed.): New research on autoantibodies. Nova Science Publishers,
Hauppauge (New York). pp. 61-86.
2. La Cava A, Hahn BH. 2008. Immunotherapy with Ig-derived peptides in SLE: Current
status and directions. In Seward TI (Ed.): Progress in systemic lupus erythematosus
Page 5 - Curriculum vitae
di [cognome] / of [surname]
3.
4.
5.
6.
7.
8.
9.
research. Nova Science Publishers, Hauppauge (New York). pp. 131-153.
La Cava A. 2008. Regulatory T cells. In Pontell EB (Ed.): Immune tolerance research
developments. Nova Science Publishers, Hauppauge (New York). pp. 51-74.
Iikuni N, La Cava A. 2008. Murine lupus models for the study of human systemic lupus
erythematosus. In La Cava A. (Ed.): Recent research developments in rheumatology.
Transworld Research Network, Trivandrum, pp. 55-78.
La Cava A. 2008. New developments in the management of systemic lupus
erythematosus. In La Cava A (Ed.): Recent research developments in rheumatology.
Transworld Research Network, Trivandrum, pp. 79-97.
Hahn BH, Singh RR, Singh RP, Wong M, Skaggs B, Tsao BP, La Cava A. 2009. Cellular
regulation of autoimmunity. In Pisetsky D (Ed.): The American College of Rheumatology at
75: A diamond jubilee. John Wiley & Sons, Inc., Hoboken, pp. 125-131.
La Cava A. 2010. Immunotherapy with Ig-derived peptides in systemic lupus
erythematosus. In Facinelli BC (Ed.): Immunotherapy: activation, suppression
and treatments. Nova Science Publishers, Hauppauge, pp. 181-200.
Mahanian M, Fiala M, Mizwicki M, La Cava A. 2012. Immune modulation of inflammation
in neurodegenerative diseases: Alzheimer’s disease and amyotrophic lateral sclerosis.
In Aggarwal (Ed.): Inflammation, life style and chronic diseases: the silent link. CRC
Press, Taylor & Francis, Boca Raton, pp. 41-56.
La Cava A. 2012. Immunoregulatory cells in SLE. In Hahn BH and Wallace DJ (Ed.):
Dubois’ Lupus Erythematosus. 8th Edition. Lippincott Williams & Wilkins, New York, pp.
104-114.
Books (Editor) :
1. “Recent research developments in rheumatology”. La Cava A. (Ed.) 2008. Transworld
Research Network, Trivandrum.
2. “An update on the pathogenesis of immune dysregulation in autoimmunity”. La Cava A.
(Ed.) vol. 13-14; 2008. Frontiers in Bioscience, New York.
3. “Regulatory immune cell subsets in autoimmunity”. La Cava A. (Ed.) Autoimmunity vol. 1;
2010. Informa Healthcare, New York.
TRATTAMENTO DEI DATI
PERSONALI, INFORMATIVA E
CONSENSO
Il D.Lgs. 30/6/2003, n. 196 “Codice in materia di protezione dei dati personali” regola il
trattamento dei dati personali, con particolare riferimento alla riservatezza, all’identità personale
e al diritto di protezione dei dati personali; l’interessato deve essere previamente informato del
trattamento .
La norma in considerazione intende come “trattamento” qualunque operazione o complesso di
operazioni concernenti la raccolta, la registrazione, l’organizzazione, la conservazione, la
consultazione, l’elaborazione, la modifica, la selezione, l’estrazione, il raffronto, l’utilizzo,
l’interconnessione, il blocco, la comunicazione, la diffusione, la cancellazione e la distruzione di
dati, anche se non registrati in una banca dati.
In relazione a quanto riportato, autorizzo il CNR al trattamento dei dati contenuti nel presente
curriculum vitae e nella documentazione della quale fa parte integrante, sollevandolo da ogni
responsabilità e autorizzandolo alla pubblicazione, nel sito web del CNR, della relazione
inerente alle proprie ricerche svolte durante il soggiorno finanziato dal CNR nell’ambito del
Programma STM . Inoltre acconsento all’aggiornamento delle informazioni intranet che mi
riguardano sia relative le pubblicazioni sia alle ricerche svolte.
( barrare la casella)
Prof. Antonio La Cava
Page 6 - Curriculum vitae
di [cognome] / of [surname]
x Si, acconsento